Journal of global antimicrobial resistance最新文献

筛选
英文 中文
Characterization of Klebsiella pneumoniae Carbapenemase (KPC)-14, a KPC Variant Conferring Resistance to Ceftazidime-Avibactam in the Extensively Drug-resistant ST463 Pseudomonas aeruginosa Clinical Isolate.
IF 3.7 3区 医学
Journal of global antimicrobial resistance Pub Date : 2025-03-10 DOI: 10.1016/j.jgar.2025.03.004
Yanyan Xiao, Le Wang, Huiqiong Jia, Yan Jiang, Yue Li, Jiamin Han, Shengchao Li, Yaxi Gu, Qing Yang
{"title":"Characterization of Klebsiella pneumoniae Carbapenemase (KPC)-14, a KPC Variant Conferring Resistance to Ceftazidime-Avibactam in the Extensively Drug-resistant ST463 Pseudomonas aeruginosa Clinical Isolate.","authors":"Yanyan Xiao, Le Wang, Huiqiong Jia, Yan Jiang, Yue Li, Jiamin Han, Shengchao Li, Yaxi Gu, Qing Yang","doi":"10.1016/j.jgar.2025.03.004","DOIUrl":"https://doi.org/10.1016/j.jgar.2025.03.004","url":null,"abstract":"<p><strong>Objectives: </strong>We studied two Klebsiella pneumoniae carbapenemase (KPC)-14 variants from clinical Pseudomonas aeruginosa isolates (C137 and C159) to better understand the genomic diversity, mechanisms, and genes that confer antibiotic resistance and pathogenicity.</p><p><strong>Methods: </strong>Genomic DNA from C137/159 was subjected to Illumina and Oxford Nanopore sequencing. Horizontal transmission of the plasmid was evaluated using cloning experiments. The expression of efflux pumps, the outer membrane protein OprD, and the enzyme AmpC was quantified using qRT-PCR. The detectability of KPC-14 was evaluated using different methods, and biofilm formation assays and growth curves were assessed.</p><p><strong>Results: </strong>C137 and C159, sequence type 463 ExoU-positive multidrug-resistant strains, were concurrently resistant to carbapenems and ceftazidime-avibactam (CZA). Both strains possessed five intrinsic antimicrobial resistance genes (fosA, catB7, crpP, bla<sub>PAO</sub>, and a bla<sub>OXA-486</sub> variant) as well as bla<sub>KPC-14</sub>. In strain C137, bla<sub>KPC-14</sub> was located on a plasmid (pC137). Both strains expressed the bla<sub>KPC-14</sub> gene, concurrent inactivation of OprD, overexpression of the MexX efflux pump, and a pronounced capacity for biofilm formation. The genomic environment of KPC-14 consisted of IS26/IS26/TnpR_Tn3/ISKpn27/ISKpn6/IS26, which classified it as pseudo-compound transposon (PCT). IS26-mediated PCTs may store a variety of resistance genes, including bla<sub>KPC-2</sub> and KPC variants, which are currently disseminating in this region.</p><p><strong>Conclusion: </strong>The KPC-14 variant presents significant challenges for clinical treatment. The bla<sub>KPC-14</sub> gene carried by PCTs was integrated into the chromosome and exhibited stability throughout bacterial inheritance. Our research highlights the need for improved clinical surveillance of KPC-producing P. aeruginosa.</p>","PeriodicalId":15936,"journal":{"name":"Journal of global antimicrobial resistance","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143615669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Plasmidome analyses of Klebsiella pneumoniae coproducing blaKPC-2 and blaNDM-1 in Southern Brazil: Characterization of Mobile Genetic Elements.
IF 3.7 3区 医学
Journal of global antimicrobial resistance Pub Date : 2025-03-08 DOI: 10.1016/j.jgar.2025.02.020
M K H Berdichevski, R R Guerra, D C Pereira, C M Wilhem, P O Barth, M C Silveira, F C Z Volpato, C Rocha-de-Souza, R M Carrassai, A P Carvalho-Assef, A F Martins, A L Barth
{"title":"Plasmidome analyses of Klebsiella pneumoniae coproducing blaKPC-2 and blaNDM-1 in Southern Brazil: Characterization of Mobile Genetic Elements.","authors":"M K H Berdichevski, R R Guerra, D C Pereira, C M Wilhem, P O Barth, M C Silveira, F C Z Volpato, C Rocha-de-Souza, R M Carrassai, A P Carvalho-Assef, A F Martins, A L Barth","doi":"10.1016/j.jgar.2025.02.020","DOIUrl":"https://doi.org/10.1016/j.jgar.2025.02.020","url":null,"abstract":"<p><strong>Objectives: </strong>Infections due to carbapenemase-producing Enterobacterales harboring more than one carbapenemase-encoding gene spreads mainly by plasmid and transposon mobilization.</p><p><strong>Objectives: </strong>Analyze the mobile genetic elements carrying bla<sub>KPC</sub> and bla<sub>NDM</sub> of K. pneumoniae carbapenemase co-producers (KpKN).</p><p><strong>Methods: </strong>K. pneumoniae isolates with reduced susceptibility to carbapenems were obtained from 2016 to 2023. To evaluate the genetic environment of KpKN, 22 isolates were selected for antimicrobial susceptibility testing and whole-genome sequencing (WGS).</p><p><strong>Results: </strong>The bla<sub>KPC-2</sub> gene was carried mainly by IncN/IncFIB, a novel co-integrated plasmid in the Tn4401b transposon. The bla<sub>NDM-1</sub> was disseminated in the only two KpKN isolates recovered before 2020 by IncHI1B/IncFIB plasmid type, in the Tn3000 transposon. Noteworthy, isolates obtained since 2020 showed the bla<sub>NDM-1</sub> gene carried by IncA/C in an IS26-flanked pseudo-composite transposon containing ISCR1, which also had genes that confer resistance to sulfonamides, aminoglycosides, macrolides, quinolones, amphenicols, tetracyclines, rifampicin, sulfonamide, and trimethoprim. The isolates belong mainly to ST11 and ST16.</p><p><strong>Conclusions: </strong>The plasmid and transposon changes during the different periods could be related to higher dissemination of the bla<sub>NDM-1</sub> and the large number of resistance genes present in the IS26-flanked transposon may have increased the co-selection of this plasmid through the wide use of antimicrobials during the pandemic.</p>","PeriodicalId":15936,"journal":{"name":"Journal of global antimicrobial resistance","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143597221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effectiveness and safety of ceftazidime-avibactam in Chinese patients with hospital-acquired pneumonia, including ventilator-associated pneumonia: a Phase 4, multi-centre, open-label study.
IF 3.7 3区 医学
Journal of global antimicrobial resistance Pub Date : 2025-03-08 DOI: 10.1016/j.jgar.2025.03.001
Jinyi Yuan, Fei Guo, Aimin Li, NanYan Xu, Xiaoyue Chang, Zuke Xiao, Huiqing Zeng, Hua Qiao, Liangfa Tang, Yunsong Yu, Bin Liu, Panpan Wang, Paurus Irani, Rienk Pypstra, Junchao Lu, Fanglei Liu, Yuting Mu, Haihui Huang, Yingyuan Zhang
{"title":"Effectiveness and safety of ceftazidime-avibactam in Chinese patients with hospital-acquired pneumonia, including ventilator-associated pneumonia: a Phase 4, multi-centre, open-label study.","authors":"Jinyi Yuan, Fei Guo, Aimin Li, NanYan Xu, Xiaoyue Chang, Zuke Xiao, Huiqing Zeng, Hua Qiao, Liangfa Tang, Yunsong Yu, Bin Liu, Panpan Wang, Paurus Irani, Rienk Pypstra, Junchao Lu, Fanglei Liu, Yuting Mu, Haihui Huang, Yingyuan Zhang","doi":"10.1016/j.jgar.2025.03.001","DOIUrl":"https://doi.org/10.1016/j.jgar.2025.03.001","url":null,"abstract":"<p><strong>Background: </strong>Ceftazidime-avibactam was approved in patients with hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), based on the multinational Phase 3 REPROVE study. This study assessed efficacy and safety of ceftazidime-avibactam in Chinese adults with HAP/VAP.</p><p><strong>Methods: </strong>This was a Phase 4, prospective, multi-centre, open-label study, conducted at 42 sites in China. Patients with HAP/VAP received ceftazidime-avibactam 2.5 g by 2-hour IV infusion every 8 hours for 7-14 days. Primary efficacy endpoint was clinical response at the test-of-cure (TOC) visit in the clinical modified intent-to-treat (cMITT) analysis set. Secondary endpoints included microbiological response at TOC (microbiological modified intent-to-treat; [mMITT] analysis set) and all-cause mortality at TOC and Day 28. Results were summarized descriptively.</p><p><strong>Results: </strong>Of 257 screened individuals, 235 were treated with ceftazidime-avibactam (safety analysis set); 71% were male; median age was 67 years. Klebsiella pneumoniae (n = 49 [61.3%]) and Pseudomonas aeruginosa (n = 16 [20.0%]) were the most frequently isolated baseline pathogens. Clinical cure at TOC was achieved in 62.7% patients (131/209, 95% CI: [56.0, 69.0]) in the cMITT analysis set. Favourable microbiological responses at TOC occurred in 51.3% (41/80, 95% CI: [40.4, 62.0]) patients (mMITT analysis set). All-cause mortality was 5.7% (12/209; 95% CI: 3.2, 9.6) at TOC and Day 28 (cMITT analysis set). No new safety signals were identified.</p><p><strong>Conclusions: </strong>Ceftazidime-avibactam was effective in Chinese patients with HAP/VAP, and results were consistent with the Phase 3 REPROVE study. These findings support the use of ceftazidime-avibactam as a potential treatment option in Chinese adults with HAP/VAP.</p>","PeriodicalId":15936,"journal":{"name":"Journal of global antimicrobial resistance","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143597219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Therapeutic effects of zinc nanoparticles green synthesized by Ferula macercolea extract against chronic toxoplasmosis in mice. 用阿魏提取物合成的绿色锌纳米粒子对小鼠慢性弓形虫病的治疗效果。
IF 3.7 3区 医学
Journal of global antimicrobial resistance Pub Date : 2025-03-07 DOI: 10.1016/j.jgar.2025.03.002
Abdullah D Alanazi, Areej Jameel Alghabban
{"title":"Therapeutic effects of zinc nanoparticles green synthesized by Ferula macercolea extract against chronic toxoplasmosis in mice.","authors":"Abdullah D Alanazi, Areej Jameel Alghabban","doi":"10.1016/j.jgar.2025.03.002","DOIUrl":"https://doi.org/10.1016/j.jgar.2025.03.002","url":null,"abstract":"<p><strong>Objectives: </strong>The present study aimed to green synthesize and characterize the zinc nanoparticles (ZNP) and evaluate its potency to control Toxoplasma gondii infection in mice by stimulating the immune system, antioxidant activity, and anti-inflammatory effects.</p><p><strong>Methods: </strong>By in vivo, T. gondii infected mice were orally treated by ZNP (5-20 mg/kg) for 14 days. The number and size of tissue cysts, oxidant-antioxidant enzymes, the expression of inflammatory cytokines, apoptotic, and pathogenicity-related factors were evaluated by real-time polymerase chain reaction (PCR).</p><p><strong>Results: </strong>ZNP ranged in size from 10-70 nm with an average size of 45.7±19.4 nm. ZNP treatment resulted in a significant reduction in the number and size of tissue cysts (p<0.05). The oral administration of infected mice with ZNP caused a considerable decrease in malondialdehyde levels and a marked increase (p<0.001) in the activity of the antioxidant enzymes glutathione peroxidase and superoxide dismutase. ZNP administration triggered a significant reduction in the expression levels of the genes of interleukin-1β, tumor necrosis factor-α, nuclear factor kappa B, bradyzoite antigen-1, and B-cell lymphoma-2. Conversely, there was an increase in the expression levels of the genes of IL-10, Serpin A3k, caspase-3, and Bcl-2-associated X protein (P < 0.001).</p><p><strong>Conclusion: </strong>In summary, the recent investigation illustrated that ZNP demonstrates promising in vivo effects against T. gondii infection in mice. These effects are ascribed to its antioxidant properties, anti-inflammatory characteristics through the inhibition the specific inflammatory cytokines, and its ability to inhibit pathogenicity in mice without any observable signs of toxicity.</p>","PeriodicalId":15936,"journal":{"name":"Journal of global antimicrobial resistance","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143585914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Streptococcus pyogenes M1UK presence in China in 2018
IF 3.7 3区 医学
Journal of global antimicrobial resistance Pub Date : 2025-03-07 DOI: 10.1016/j.jgar.2025.02.017
Dingle Yu , Yuejie Zheng , Yunsheng Chen , Yuanhai You , Yonghong Yang
{"title":"Streptococcus pyogenes M1UK presence in China in 2018","authors":"Dingle Yu ,&nbsp;Yuejie Zheng ,&nbsp;Yunsheng Chen ,&nbsp;Yuanhai You ,&nbsp;Yonghong Yang","doi":"10.1016/j.jgar.2025.02.017","DOIUrl":"10.1016/j.jgar.2025.02.017","url":null,"abstract":"","PeriodicalId":15936,"journal":{"name":"Journal of global antimicrobial resistance","volume":"42 ","pages":"Pages 175-176"},"PeriodicalIF":3.7,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143585982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Temporal trends of enterococcal and vancomycin-resistant Enterococcus faecium bacteraemia in the northern Dutch-German cross-border region: A 10-y multicentre analysis (2013–2022)
IF 3.7 3区 医学
Journal of global antimicrobial resistance Pub Date : 2025-03-05 DOI: 10.1016/j.jgar.2025.02.022
Cansu Cimen , Andreas Voss , Josef Hellkamp , Axel Hamprecht , Matthijs S. Berends
{"title":"Temporal trends of enterococcal and vancomycin-resistant Enterococcus faecium bacteraemia in the northern Dutch-German cross-border region: A 10-y multicentre analysis (2013–2022)","authors":"Cansu Cimen ,&nbsp;Andreas Voss ,&nbsp;Josef Hellkamp ,&nbsp;Axel Hamprecht ,&nbsp;Matthijs S. Berends","doi":"10.1016/j.jgar.2025.02.022","DOIUrl":"10.1016/j.jgar.2025.02.022","url":null,"abstract":"<div><h3>Objective</h3><div>To analyse the trends in occurrence of enterococcal and vancomycin-resistant <em>Enterococcus faecium</em> (VREfm) bacteraemia in the northern Dutch-German cross-border region.</div></div><div><h3>Methods</h3><div>A retrospective cross-sectional study was conducted using positive blood culture results from two university hospitals, the University Medical Centre Groningen (UMCG) and the Klinikum Oldenburg (KOL) between 1 January 2013 to 31 December 2022.</div></div><div><h3>Results</h3><div>Over the 10-y period, 738 enterococcal bacteraemia episodes were observed at KOL and 1091 at UMCG, involving 685 and 999 patients, respectively. <em>E. faecium</em> was the predominant species in both institutions (60.3% at KOL and 60.8% at UMCG). The median age of patients with enterococcal, <em>E. faecium, E. faecalis</em> and VREfm bacteraemia was consistently higher at KOL than at UMCG (<em>p=</em> <em>.029</em>). In both institutions, over half of the enterococcal bacteraemia cases (53.4% at KOL, 55.8% at UMCG) were observed in intensive care units and haematology/oncology wards. From 2018 to 2022, UMCG had higher overall incidence rates of <em>E. faecium</em>, and <em>E. faecalis</em> bacteraemia, while KOL had a significantly higher incidence of VREfm (0.56 vs. 0.05 per 10,000 patient-d, <em>p&lt;</em> <em>.0001</em>). There was a significant upward trend in VREfm bacteraemia cases (<em>p=</em> <em>.01</em>) and in the proportion of VREfm among bacteraemia caused by <em>E. faecium</em> (<em>p=</em> <em>.027</em>) at KOL, but such a trend was not observed at UMCG during the study period.</div></div><div><h3>Conclusions</h3><div>The results reveal a significant difference in VREfm bacteraemia occurrences between a German and Dutch hospital in a cross-border region, reflecting national trends yet showing regional variation.</div></div>","PeriodicalId":15936,"journal":{"name":"Journal of global antimicrobial resistance","volume":"42 ","pages":"Pages 187-194"},"PeriodicalIF":3.7,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143585912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Detection of a genetically related carbapenemase-producing Escherichia coli ST167 in clinical and environmental isolates: Evidence for clonal spread of carbapenemase-producing Enterobacteriaceae in humans and the environment in Iowa, United States
IF 3.7 3区 医学
Journal of global antimicrobial resistance Pub Date : 2025-03-05 DOI: 10.1016/j.jgar.2025.02.021
Hanseob Shin , David M. Cwiertny , Megan J. Nelson , Ryan T. Jepson , Michael A. Pentella , Darrin A. Thompson
{"title":"Detection of a genetically related carbapenemase-producing Escherichia coli ST167 in clinical and environmental isolates: Evidence for clonal spread of carbapenemase-producing Enterobacteriaceae in humans and the environment in Iowa, United States","authors":"Hanseob Shin ,&nbsp;David M. Cwiertny ,&nbsp;Megan J. Nelson ,&nbsp;Ryan T. Jepson ,&nbsp;Michael A. Pentella ,&nbsp;Darrin A. Thompson","doi":"10.1016/j.jgar.2025.02.021","DOIUrl":"10.1016/j.jgar.2025.02.021","url":null,"abstract":"<div><h3>Background</h3><div>Carbapenemase-producing Enterobacteriaceae (CPE) are listed by the World Health Organization as one of the critical priority pathogens needing urgent attention to address global resistance to antimicrobials. Thus, the transmission and epidemiology of CPEs need to be studied via One Health perspectives.</div></div><div><h3>Methods</h3><div>An environmental CPE, referred to as BO1, was isolated from a creek in Northwest Iowa using a Colilert system (IDEXX, Westbrook, ME, USA). The presence of carbapenemase was examined using the modified carbapenem inactivation test, and then phenotypic resistance was determined using a Sensititre Complete Automated AST System (Thermo Fisher Scientific, Roskilde, Denmark). Whole-genome sequencing was performed and analysed to compare with clinical CPEs.</div></div><div><h3>Results</h3><div>BO1, carrying <em>bla</em><sub>NDM-5</sub>, was isolated from a creek in Northwest Iowa. BO1 exhibited resistance to 15 antimicrobials and was defined as an extensively drug-resistant organism. BO1 was also identified as ST167, which is well known as an emerging high-risk clone, and IncFIA- and IncQ1-type conjugatable plasmids were identified within the BO1 genome. The genetic environment of <em>bla</em><sub>NDM-5</sub> was highly conserved as <em>bla</em><sub>NDM</sub>-<em>ble</em><sub>MBL</sub>-<em>trpF</em>-<em>dsbD</em> in all strains studied. Interestingly, single-nucleotide polymorphism analysis revealed that BO1 shared only 1, 4 and 12 single-nucleotide polymorphisms with three different clinical strains from patients at Iowa health care facilities.</div></div><div><h3>Conclusions</h3><div>The occurrence of BO1 was temporally and spatially close to that of one clinical strain, IA0018, implying the clonal spread of CPEs among humans and the environment, although the source and directionality of this spread remains unknown. This report illustrates the need for the strict control of CPEs in health care facilities and continuous surveillance within clinical and environmental settings to trace and prevent CPE transmission.</div></div>","PeriodicalId":15936,"journal":{"name":"Journal of global antimicrobial resistance","volume":"42 ","pages":"Pages 154-160"},"PeriodicalIF":3.7,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143585976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ST11 Carbapenem-Resistant Klebsiella pneumoniae Clone Harboring Capsular Type KL25 became the primarily prevalent capsular serotypes in a Tertiary Teaching Hospital in China.
IF 3.7 3区 医学
Journal of global antimicrobial resistance Pub Date : 2025-03-04 DOI: 10.1016/j.jgar.2025.02.019
Jing Wang, Qi Wang, Ruiqi Wang, Ruobing Wang, Jianbang Kang, Jinju Duan, Hui Wang
{"title":"ST11 Carbapenem-Resistant Klebsiella pneumoniae Clone Harboring Capsular Type KL25 became the primarily prevalent capsular serotypes in a Tertiary Teaching Hospital in China.","authors":"Jing Wang, Qi Wang, Ruiqi Wang, Ruobing Wang, Jianbang Kang, Jinju Duan, Hui Wang","doi":"10.1016/j.jgar.2025.02.019","DOIUrl":"https://doi.org/10.1016/j.jgar.2025.02.019","url":null,"abstract":"<p><strong>Objective: </strong>The spread of carbapenem-resistant Klebsiella pneumoniae (CRKP) that produces Klebsiella pneumoniae carbapenemase-2 (KPC-2) has garnered significant attention due to their increasing prevalence. In China, the dissemination of KPC-2-producing CRKP is predominantly linked to sequence type 11 (ST11), with the capsular serotypes KL47 and KL64 being the primary capsular identified.</p><p><strong>Methods: </strong>Sixty-four CRKP-ST11 strains were collected from 2020 to 2023. We performed whole-genome sequencing on all isolated ST11-CRKP strains. Antibiotic susceptibilities were tested with VITEK 2 systems. Growth curve test and in vitro competition experiments were used to assess growth adaptability of different capsular type isolates. Moreover, the biofilm assessment and phagocytosis assay were performed to evaluate the virulence of the CRKP isolates.</p><p><strong>Results: </strong>During the observed period, a no subclonal shift was perceived within the prevailing ST11-CRKP clone, wherein the previously dominant KL64 and KL47 serotypes have been largely supplanted by the KL25 serotype since 2022. The ST11-KL25-CRKP strain significantly outgrew both ST11-KL64-CRKP and ST11-KL47-CRKP. Additionally, ST11-KL25-CRKP displayed a greater enhanced capacity to form biofilms than ST11-KL64-CRKP and ST11-KL47-CRKP. Furthermore, the ST11-KL25-CRKP strain demonstrated enhanced resistance to phagocytosis than both of its counterparts.</p><p><strong>Conclusion: </strong>ST11-KL25-CRKP possesses a remarkable level of adaptability and has the potential to regionally replace ST11-KL64-CRKP as the predominant strain in the region. And the novel and high-risk ST11-KL25-CRKP strain may indicate stronger virulence.</p>","PeriodicalId":15936,"journal":{"name":"Journal of global antimicrobial resistance","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143573174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ISAC Information Page
IF 3.7 3区 医学
Journal of global antimicrobial resistance Pub Date : 2025-03-01 DOI: 10.1016/S2213-7165(25)00053-0
{"title":"ISAC Information Page","authors":"","doi":"10.1016/S2213-7165(25)00053-0","DOIUrl":"10.1016/S2213-7165(25)00053-0","url":null,"abstract":"","PeriodicalId":15936,"journal":{"name":"Journal of global antimicrobial resistance","volume":"41 ","pages":"Page i"},"PeriodicalIF":3.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143563175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ISAC News and Updates
IF 3.7 3区 医学
Journal of global antimicrobial resistance Pub Date : 2025-03-01 DOI: 10.1016/j.jgar.2025.02.016
{"title":"ISAC News and Updates","authors":"","doi":"10.1016/j.jgar.2025.02.016","DOIUrl":"10.1016/j.jgar.2025.02.016","url":null,"abstract":"","PeriodicalId":15936,"journal":{"name":"Journal of global antimicrobial resistance","volume":"41 ","pages":"Pages 290-291"},"PeriodicalIF":3.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143531394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信